The Drug Discovery Services Market is undergoing significant expansion as pharmaceutical and biopharmaceutical companies increase their investments in research and development. Valued at US$14.89 billion in 2024, the market is projected to grow at a robust CAGR of 10.7%, reaching US$16.36 billion in 2025 and US$27.23 billion by 2030. This growth is driven by rising R&D activity, the high cost of internal drug development, increasing reliance on contract research organizations (CROs), and a continuous need for specialized analytical testing.
As the global therapeutic pipeline expands—particularly in areas such as oncology, rare diseases, immunology, and neurology—companies are outsourcing more discovery activities to experienced service providers. These partners deliver advanced scientific capabilities, modern technologies, and cost-effective solutions that accelerate early-stage research and improve overall drug development success rates.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129
Key Market Drivers 1. Rising R&D Expenditure Among Pharmaceutical and Biopharmaceutical Companies
Pharmaceutical and biotech firms continue to increase their investments in drug discovery to support expanding therapeutic pipelines. The development of biologics, gene therapies, cell therapies, and novel small molecules requires sophisticated R&D infrastructure, which many companies prefer to outsource to reduce timelines and costs.
2. Outsourcing of Analytical and Specialized Testing
As discovery science becomes more complex, the need for high-end analytical testing, toxicology studies, high-throughput screening, and ADME/PK services increases. Outsourcing these functions enables companies to access specialized expertise, standardized workflows, and advanced instrumentation—significantly improving the efficiency of drug discovery programs.
3. Focus on Rare Diseases and Orphan Drug Research
The rising number of research initiatives targeting rare diseases and orphan drugs is creating additional demand for drug discovery services. Companies working in these niche areas often require customized assays, advanced modeling techniques, and expert-driven studies, making outsourcing an essential part of their strategy.
4. High Cost and Complexity of In-House Drug Development
Building and maintaining internal drug discovery infrastructure—including laboratories, equipment, and scientific talent—is highly resource-intensive. Contract research organizations (CROs) offer a cost-effective alternative by providing ready access to multidisciplinary teams and cutting-edge technologies.
5. Advancements in Drug Discovery Technologies
Modern technologies such as: • AI and machine learning–based drug design • Structure-based drug design • High-throughput screening • CRISPR gene editing • Combinatorial chemistry • In-silico and computational modeling
are creating new opportunities for enhanced accuracy, faster timelines, and lower costs. As these technologies evolve, demand for specialized drug discovery services continues to rise across both small and large pharmaceutical companies.
Market Segmentation by Service Type
The drug discovery services market is broadly categorized into chemistry services and biology services.
Chemistry Services Dominated the Market in 2024
The chemistry services segment accounted for the largest market share in 2024 due to strong demand for: • Combinatorial chemistry • Medicinal chemistry • Analytical chemistry • Structure-based drug design • Fragment-based drug discovery
These services are essential for identifying and optimizing lead molecules with favorable therapeutic profiles. As the need for safe, effective, and high-quality drugs increases globally, the chemistry segment is expected to continue leading the market.
Biology Services Support Biologics and Advanced Therapies
Biology services—covering assays, cell-based studies, target validation, pharmacology, and bioinformatics—are becoming increasingly important as biologics gain traction. Biopharmaceutical companies are prioritizing biologic drug discovery due to: • High clinical success rates of biologics • Rising demand for targeted therapies • Growth of biosimilars • Increasing prevalence of chronic and autoimmune disorders
Because biologics require specialized research capabilities and complex development workflows, companies are outsourcing more biology-focused services to experienced CROs.
Market Segmentation by Drug Type: Biologics vs. Small Molecules
The drug type segment is divided into: • Biologics • Small molecules
Biologics Segment Showing Rapid Growth
Biologics—including monoclonal antibodies, recombinant proteins, and advanced modalities—continue to gain prominence due to their high specificity and therapeutic potential. Several factors are fueling growth in this segment: • Increased biopharma investments • Rising complexity of biologic drug development • High cost of biologics and the need for efficient discovery approaches • Growing demand for biosimilars to address patent expirations • Outsourcing of biologics R&D to CROs with specialized facilities
The shift toward biologics is expected to reshape drug discovery workflows, making biology-focused services a critical market driver over the next decade.
Regional Insights
The drug discovery services market is segmented into: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
North America Leads the Global Market
North America dominated the market in 2024 due to: • A large base of established CROs • High R&D spending by pharmaceutical and biotech companies • Growing biosimilars and biologics development • Strong presence of big pharma and academic institutions • Widespread adoption of advanced discovery technologies
The US remains a major hub for early-stage drug discovery, benefiting from a strong regulatory framework, skilled workforce, and cutting-edge research infrastructure.
Asia Pacific is the Fastest-Growing Region
The Asia-Pacific (APAC) drug discovery services market is expanding rapidly due to: • Growth of pharmaceutical and biopharmaceutical manufacturing • Increasing number of CROs in China, India, and South Korea • Lower operational costs compared to Western markets • Favorable government policies promoting R&D • Less-stringent regulations for early-stage discovery processes
APAC is emerging as a preferred outsourcing destination, particularly for chemistry, biology, and preclinical research services.
Key Players in the Market
Prominent companies operating in the global drug discovery services market include: • Charles River Laboratories (US) • Thermo Fisher Scientific (US) • WuXi AppTec (China) • Pharmaron (China) • Labcorp (US) Other notable players contribute significantly through innovations in discovery platforms, AI-driven drug development, and biologics research.
Conclusion
The Drug Discovery Services Market is poised for sustained growth driven by rising pharmaceutical R&D spending, increasing outsourcing trends, and strong advances in drug discovery technologies. Chemistry services remain the backbone of early discovery, while biologics research is gaining momentum due to its therapeutic advantages. With North America leading the market and Asia Pacific emerging as a fast-growing outsourcing hub, global CROs are well-positioned to meet the rising demand for efficient, cost-effective, and innovative drug discovery solutions through 2030.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html